Search Results - "Nichols, T C"

Protease-Resistant Insulin-Like Growth Factor (IGF)-Binding Protein-4 Inhibits IGF-I Actions and Neointimal Expansion in a Porcine Model of Neointimal Hyperplasia by Nichols, T. C, Busby, W. H, Merricks, E, Sipos, J, Rowland, M, Sitko, K, Clemmons, D. R

“…IGF-I has been shown to play a role in the progression of atherosclerosis in experimental animal models. IGF-binding protein-4 (IGFBP-4) binds to IGF-I and…”
Get full text

Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia by MONAHAN, P. E, SAMULSKI, R. J, TAZELAAR, J, XIAO, X, NICHOLS, T. C, BELLINGER, D. A, READ, M. S, WALSH, C. E

“…A recombinant adeno-associated virus (rAAV) vector carrying the human factor IX cDNA was tested for safety and therapeutic gene expression in a canine model of…”
Get full text

Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies by Nichols, T. C., Hough, C., Agersø, H., Ezban, M., Lillicrap, D.

“…Summary Animal models of inherited bleeding disorders are important for understanding disease pathophysiology and are required for preclinical assessment of…”
Get full text

Persistent expression of canine factor IX in hemophilia B canines by CHAO, H, SAMULSKI, R. J, BELLINGER, D. A, MONAHAN, P. E, NICHOLS, T. C, WALSH, C. E

“…We previously demonstrated that direct intramuscular injection of recombinant adeno-associated virus (rAAV) carrying the human FIX (hFIX) cDNA can safely be…”
Get full text

Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B by HARDING, T. C, KOPRIVNIKAR, K. E, NICHOLS, T. C, BELLINGER, D. A, YENDLURI, S, WAUGH, J, MCARTHUR, J, VERES, G, DONAHUE, B. A, TU, G. H, ZAYEK, N, LEW, S, SUBRAMANIAN, A, SIVAKUMARAN, A, FREY, D, HO, K, VANROEY, M. J

“…Previous experiments have demonstrated the stable expression of factor IX (FIX) protein in mice and canine models of hemophilia B following portal vein gene…”
Get full text

Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys by McCarthy, K, Stewart, P, Sigman, J, Read, M, Keith, Jr, J C, Brinkhous, K M, Nichols, T C, Schaub, R G

“…Hemophilia B therapy requires intravenous (IV) infusions of large volumes of factor IX due to the low concentration of factor IX in concentrates (approximately…”
Get more information

Improved kinetics of rIX‐FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs by NOLTE, M. W., NICHOLS, T. C., MUELLER‐COHRS, J., MERRICKS, E. P., PRAGST, I., ZOLLNER, S., DICKNEITE, G.

“…Background:  Prophylaxis of hemophilia B, at present, requires multiple infusions of human factor (F)IX concentrates per week. A FIX molecule with a prolonged…”
Get full text

An anti-αVβ3 antibody inhibits coronary artery atherosclerosis in diabetic pigs by Maile, L.A, Busby, W.H, Xi, G, Gollahan, K.P, Flowers, W, Gafbacik, N, Gafbacik, S, Stewart, K, Merricks, E.P, Nichols, T.C, Bellinger, D.A, Clemmons, D.R

“…Abstract Background and aims Diabetes is a major risk factor for the development of atherosclerosis. Hyperglycemia stimulates vascular smooth muscle cells (…”
Get full text

Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs by Agersø, H., Stennicke, H. R., Pelzer, H., Olsen, E. N., Merricks, E. P., deFriess, N. A., Nichols, T. C., Ezban, M.

“…Summary The objective of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the new recombinant FVIII compound…”
Get full text

Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide by Van Cott, K. E., Monahan, P. E., Nichols, T. C., Velander, W. H.

“…Haemophilia replacement factors, both plasma‐derived and recombinant, are in relatively short supply and are high‐cost products. This has stymied the study and…”
Get full text

Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs by Russell, K E, Read, M S, Bellinger, D A, Leitermann, K, Rup, B J, McCarthy, K P, Keith, Jr, J C, Khor, S P, Schaub, R G, Nichols, T C

“…The purpose of this paper was to establish proof of concept for administration of human recombinant F.IX (rF.IX) by inhalation for therapy of hemophilia B. The…”
Get more information

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction by Bleich, Stanley D., Nichols, Timothy C., Schumacher, Richard R., Cooke, David H., Tate, David A., Teichman, Sam L.

“…Infarct artery patency rates at 90 minutes after coronary thrombolysis using recombinant tissuetype plasminogen activator (rt-PA) with and without concurrent…”
Get full text

Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post‐transfusion elimination time of canine factor IX in hemophilia B dogs by NICHOLS, T. C., FRANCK, H. W. G., FRANCK, C. T., de FRIESS, N., RAYMER, R. A., MERRICKS, E. P.

Get full text

Porphyromonas gingivalis Bacteremia Induces Coronary and Aortic Atherosclerosis in Normocholesterolemic and Hypercholesterolemic Pigs by Brodala, Nadine, Merricks, Elizabeth P, Bellinger, Dwight A, Damrongsri, Damrong, Offenbacher, Steven, Beck, James, Madianos, Phoebus, Sotres, Daniela, Chang, Yu-Ling, Koch, Gary, Nichols, Timothy C

“…OBJECTIVES—The aim of this study was to determine whether recurrent intravenous injections with Porphyromonas gingivalis (P gingivalis), mimicking…”
Get full text

Helper‐dependent adenoviral gene therapy mediates long‐term correction of the clotting defect in the canine hemophilia A model by McCORMACK, W. M., SEILER, M. P., BERTIN, T. K., UBHAYAKAR, K., PALMER, D. J., NG, P., NICHOLS, T. C., LEE, B.

“…Background: Adenoviral vector‐mediated gene therapy might have potential for long‐term correction of the monogenic disease hemophilia A. Objective: In this…”
Get full text

Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs by KARPF, D. M., KJALKE, M., THIM, L., AGERSØ, H., MERRICKS, E. P., DEFRIESS, N., NICHOLS, T. C., EZBAN, M.

“…N8, a new recombinant factor VIII (rFVIII) compound developed for the treatment of haemophilia A, is produced in Chinese hamster ovary (CHO) cells and…”
Get full text

Preservation of Hemostatic and Structural Properties of Rehydrated Lyophilized Platelets: Potential for Long-Term Storage of Dried Platelets for Transfusion by Read, Marjorie S., Reddick, Robert L., Bode, Arthur P., Bellinger, Dwight A., Nichols, Timothy C., Taylor, Kathryn, Smith, Scott V., McMahon, Debra K., Giggs, Thomas R., Brinkhous, Kenneth M.

“…Currently, therapeutic platelet concentrates can be stored for only 5 days. We have developed a procedure that permits long-term storage of fixed and…”
Get full text

Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency by Nichols, Timothy C, Dillow, Aaron M, Franck, Helen W.G, Merricks, Elizabeth P, Raymer, Robin A, Bellinger, Dwight A, Arruda, Valder R, High, Katherine A

“…Dogs with hemophilia A, hemophilia B, von Willebrand disease (VWD), and factor VII deficiency faithfully recapitulate the severe bleeding phenotype that occurs…”
Get full text

Distinguishing Migratory and Resident Canada Geese Using Stable Isotope Analysis by Caccamise, Donald F., Reed, Lisa M., Castelli, Paul M., Wainright, Sam, Nichols, Ted C.

“…Effective management of Canada geese (Branta canadensis) requires a reliable method to determine the population affiliation of geese in the harvest. We…”
Get full text

Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog by KNUDSEN, T., KRISTENSEN, A. T., NICHOLS, T. C., AGERSØ, H., JENSEN, A. L., KJALKE, M., EZBAN, M., TRANHOLM, M.

“…Recombinant human FVIIa (rhFVIIa) corrects the coagulopathy in hemophilia A and B as well as FVII deficiency. This is also the case in dogs until canine…”
Get full text